Summary of findings 3. Doxorubicin‐based maintenance chemotherapy versus observation.
| Doxorubicin‐based maintenance chemotherapy for epithelial ovarian cancer | ||||||
| Patient or population: patients with epithelial ovarian cancer Intervention: Doxorubicin‐based maintenance chemotherapy | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Control | Doxorubicin‐based maintenance chemotherapy | |||||
| 3‐year OS Follow‐up: median 40 months | Study population | RR 1.00 (0.86 to 1.15) | 204 (2 studies) | ⊕⊕⊕⊝ moderate1 | There was no consistent effect for doxorubicin‐based maintenance chemotherapy. Overall survival for three and five years RR was 1.00 (95% CI 0.86 to 1.15 and 0.79 to 1.27, respectively) | |
| 781 per 1000 | 781 per 1000 (672 to 898) | |||||
| 5‐year OS Follow‐up: median 40 months | Study population | RR 1.00 (0.79 to 1.27) | 204 (2 studies) | ⊕⊕⊕⊝ moderate1 | ||
| 571 per 1000 | 571 per 1000 (451 to 726) | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OS: overall survival; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Downgraded as allocation concealment is unclear